ArticleFrontiers in oncology2023

Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens.

Ken Saijo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.